Drug Profile
DS 9001
Alternative Names: Anti-PCSK9-anticalin-albumod; DS-9001Latest Information Update: 07 Jun 2019
Price :
$50
*
At a glance
- Originator Pieris Pharmaceuticals
- Developer Daiichi Sankyo Company
- Class Antihyperlipidaemics; Proteins
- Mechanism of Action Immunomodulators; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 31 Jan 2017 Discontinued - Phase-I for Dyslipidaemias due to unfavourable study results in USA (SC) (Daiichi Sankyo pipeline, May 2017)
- 01 Dec 2015 Phase-I clinical trials in Dyslipidaemias in USA (SC)
- 23 Nov 2015 Preclinical trials in Undefined indication in Japan (unspecified route) before November 2015